Gaetan Jego

Title: Gaetan Jego: Innovator in Cancer Treatment

Introduction

Gaetan Jego is a notable inventor based in Dijon, France. He has made significant contributions to the field of cancer treatment through his innovative research and patented compounds. His work focuses on targeting the HSP110 protein, which plays a crucial role in cancer cell growth and stability.

Latest Patents

Gaetan Jego holds a patent for "Compounds targeting HSP110 protein for cancer treatment." This patent describes HSP110 inhibitors that bind directly to the nucleotide binding domain of HSP110, effectively blocking the phosphorylation of STAT3. This action inhibits cancer cell growth and affects MyD88 stability. The patent outlines a compound of formula (I) intended for the treatment of HSP110-associated cancers, such as colorectal cancer and lymphoma. An exemplary compound was tested on a syngeneic model, where mouse colon cancer CT-26 cells were injected into Balb/c mice, as well as on a NOD/SCID model with human colorectal cancer HCT116 cells. In these models, the compound induced tumor regression, which was linked to the inhibition of other tumorigenic functions associated with HSP110, including resistance to apoptosis and the induction of pro-tumor macrophages. Furthermore, the compound demonstrated efficacy against large B cell lymphoma cell lines (DLBCL) by altering the interaction between HSP110 and MyD88, leading to the degradation of the oncogene MyD88. Notably, it has been shown to act synergistically with other anti-cancer agents, including tyrosine kinase inhibitors like Ibrutinib.

Career Highlights

Throughout his career, Gaetan Jego has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Caen Normandie. His research has significantly advanced the understanding of cancer treatment and has the potential to improve therapeutic outcomes for patients.

Collaborations

Gaetan has collaborated with notable colleagues, including Carmen Garrido Fleury and Daniel Gonzalez. Their combined expertise has contributed to the success of his research endeavors.

Conclusion

Gaetan Jego is a pioneering inventor whose work in targeting the HSP110 protein represents a significant advancement in cancer treatment. His innovative compounds and research have the potential to change the landscape of cancer therapies, offering hope for improved patient outcomes.